Biogen and Eisai Co., Ltd. announced that the FDA has extended the review period by three months for the BLA for aducanumab, an investigational treatment for Alzheimer’s disease.
Why sign up with Medthority?
Develop your knowledge with our disease and condition focused Learning Zones
Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines
Personalised dashboard providing updates and recommendations for content within your areas of interest